Mylan introduces Levetiracetam to treat seizures

Mylan Inc. (Nasdaq: MYL) today announced that its Mylan Institutional business has launched Levetiracetam in Sodium Chloride Injection, 500 mg/100 mL, 1000 mg/100 mL and 1500 mg/100 mL, for intravenous use. Mylan's launch of this new product, which has been approved by the U.S. Food and Drug Administration (FDA), marks the first time that multiple strengths (500 mg, 1000 mg and 1500 mg) of premixed Levetiracetam will be supplied in ready-to-administer bags of Sodium Chloride Injection (100 mL). This product is an antiepileptic drug indicated for certain types of seizures.

Mylan CEO Heather Bresch said: "The launch of this product is another example of Mylan's commitment to deliver new and innovative products to our institutional customers. We are excited to be the first and only company to offer three strengths of Levetiracetam in ready-to-administer bags, which assist in the ease, accuracy and convenience of dosing. The launch reflects our commitment to innovate to meet unmet needs and our strategy of expanding Mylan's product portfolio across the generic, specialty and niche market segments."

Mylan Institutional president, Matt Erick, added: "The addition of Levetiracetam in Sodium Chloride Injection to our basket of differentiated pharmaceutical products supports our business strategy to partner with customers and increase their efficiency by offering quality and convenience in one unique packaging presentation."  

Previously, the only available version of Levetiracetam for Injection came in a vial presentation, 500 mg/5 mL. This product had U.S. sales of approximately $66.3 million for the 12 months ending Sept. 30, 2011, according to IMS Health.